🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST

Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $24.8. The average 1-year stock price forecast is 50.49% higher than the current stock price, while the lowest is $16 (-2.91%) and the highest is $39 (+136.65%).

Price Target: $24.8 (+50.49%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$16$24.8$22$39
Change-2.91%+50.49%+33.50%+136.65%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy121213888
Buy555222
Hold222101111
Sell000000
Strong Sell000000
Total191920202121

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Buy
Reiterates
$35 → $24
BuyReiterates$35 → $24+45.63%Nov 17, 2026
Morgan Stanley
Morgan Stanley
Hold
Maintains
$22
HoldMaintains$22+33.50%Nov 16, 2026
Citi
Citi
Buy
Maintains
$32 → $22
BuyMaintains$32 → $22+33.50%Nov 5, 2026
Leerink Partners
Leerink Partners
Buy
Reiterates
$33
BuyReiterates$33+100.24%Nov 5, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$36
BuyMaintains$36+118.45%Nov 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
766.11M
from 673.00M
Increased by 13.83%
Revenue Next Year
969.30M
from 766.11M
Increased by 26.52%
EPS This Year
-3.05
from -5.83
EPS Next Year
1.43
from -3.05
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
351.41M363.33M434.00M560.00M673.00M766.11M
Revenue Growth
29.66%3.39%19.45%29.03%20.18%13.83%
Operating Income
-381.74M-648.92M-569.00M-536.00M-535.00M-406.51M
Net Income
-454.03M-707.42M-607.00M-569.00M-575.00M-292.84M
EPS
-----5.83-3.05
Free Cash Flow
-----472.00M-311.00M
No. Analysts
-----19
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.1B
Avg766.1M
Low727.1M

Revenue Growth

Revenue Growth202620272028
High
57.9%
Avg
13.8%
Low
8.0%

EPS Forecast

EPS202620272028
High-1.07
Avg-3.05
Low-4.92

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-